Newer diabetes medicines and the development of diabetic retinopathy in people with diabetes
Looks at whether newer diabetes drugs delay eye damage in people with diabetes.
Plain-language title generated from the registry record
Registry title: Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
Key facts
- Where
- Alexandria, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had type 2 diabetes for more than 5 years. They must have used diabetes medicines for 2-3 years.
- Age
- 25 years and older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes for more than 5 years. Severe non-proliferative or proliferative diabetic retinopathy at the start cannot be present.
- Earlier treatment
- Taking diabetes medicines (metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors) for 2-3 years.
Main reasons for not taking part
- Gestational diabetes
- Type 1 diabetes
- Severe non-proliferative diabetic retinopathy (NPDR) at the start
- Proliferative diabetic retinopathy (PDR) at the start
- Pregnant and breastfeeding women
Read by machine on 9 November 2026.
Where in Egypt
- Alexandria University Main Hospitals - Diabetes clinics/ Ophthalmology clinicsAlexandria, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sara A Belal
- Trial code
- NCT07351786
- Record updated
- 20 January 2026
- Original description
This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.Read full original descriptionShow less
Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.
Inclusion: Diagnosed with Type 2 Diabetes for >5 years; Using Diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors) for a period of 2-3 years.
Exclusion: Gestational Diabetes; Type 1 Diabetes; Severe non-proliferative diabetic retinopathy (NPDR) at baseline; Proliferative diabetic retinopathy (PDR) at baseline; Pregnant and breastfeeding women.